ArticleProteomics2010
Quantitative analysis of the secretome of TGF-beta signaling-deficient mammary fibroblasts.
Article in Proteomics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 36 citations in OpenAlex.
- Systemic sclerosis biomarkers detection in the secretome of TGFβ1-activated primary human lung fibroblasts.Journal of proteomics · 2021Article
- The role of transforming growth factor-beta in immune suppression and chronic inflammation of squamous cell carcinomas.Molecular carcinogenesis · 2020Review
- Regulation of B cell receptor-dependent NF-κB signaling by the tumor suppressor KLHL14.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Article
- Transforming growth factor-β signaling in head and neck squamous cell carcinoma: Insights into cellular responses.Oncology letters · 2018Review
- TIMPs: versatile extracellular regulators in cancer.Nature reviews. Cancer · 2017Review
- Advancement of mass spectrometry-based proteomics technologies to explore triple negative breast cancer.Molecular bioSystems · 2016Review
- Secretome identification of immune cell factors mediating metastatic cell homing.Scientific reports · 2015Article
- Double deficiency of cathepsins B and L results in massive secretome alterations and suggests a degradative cathepsin-MMP axis.Cellular and molecular life sciences : CMLS · 2014Article
- The roles of TGFβ in the tumour microenvironment.Nature reviews. Cancer · 2013Review
- Using proteomics to uncover extracellular matrix interactions during cardiac remodeling.Proteomics. Clinical applications · 2013Review
- Mapping proteolytic processing in the secretome of gastric cancer-associated myofibroblasts reveals activation of MMP-1, MMP-2, and MMP-3.Journal of proteome research · 2013Article
- Conditioned Media Downregulates Nuclear Expression of Nrf2.Cellular and molecular bioengineering · 2013Article
- Global secretome analysis identifies novel mediators of bone metastasis.Cell research · 2012Article
- Release of TGFβig-h3 by gastric myofibroblasts slows tumor growth and is decreased with cancer progression.Carcinogenesis · 2012Article
- Lack of transforming growth factor-β signaling promotes collective cancer cell invasion through tumor-stromal crosstalk.Breast cancer research : BCR · 2012Article
- TGFβ signaling plays a critical role in promoting alternative macrophage activation.BMC immunology · 2012Article
- Loss of one Tgfbr2 allele in fibroblasts promotes metastasis in MMTV: polyoma middle T transgenic and transplant mouse models of mammary tumor progression.Clinical & experimental metastasis · 2011Article
- Progress in mining the human proteome for disease applications.Omics : a journal of integrative biology · 2011Article
- Sample preparation techniques for the untargeted LC-MS-based discovery of peptides in complex biological matrices.Journal of biomedicine & biotechnology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Transforming growth factor beta (TGF-beta) is a master regulator of autocrine and paracrine signaling pathways between a tumor and its microenvironment. Decreased expression of TGF-beta type II receptor (TbetaRII) in stromal cells is associated with increased tumor metastasis and shorter patient survival. In this study, SILAC quantitative proteomics was used to identify differentially externalized proteins in the conditioned media from the mammary fibroblasts with or without intact TbetaRII. Over 1000 proteins were identified and their relative differential levels were quantified. Immunoassays were used to further validate identification and quantification of the proteomic results. Differential expression was detected for various extracellular proteins, including proteases and their inhibitors, growth factors, cytokines, and extracellular matrix proteins. CXCL10, a cytokine found to be up-regulated in the TbetaRII knockout mammary fibroblasts, is shown to directly stimulate breast tumor cell proliferation and migration. Overall, this study revealed hundreds of specific extracellular protein changes modulated by deletion of TbetaRII in mammary fibroblasts, which may play important roles in the tumor microenvironment. These results warrant further investigation into the effects of inhibiting the TGF-beta signaling pathway in fibroblasts because systemic inhibition of TGF-beta signaling pathways is being considered as a potential cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.